Navigation Links
Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
Date:4/21/2008

Prime Therapeutics to present findings at AMCP Conference in April

ST. PAUL, Minn., April 21 /PRNewswire/ -- Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, today announced the results of its study, "Association Between Tumor Necrosis Factor (TNF) Blocker Out-of-Pocket (OOP) Expense and Member Decline to Fill Rate". The study assessed the association between decline-to-fill rates as they relate to out-of-pocket expense for members initiating TNF-blocker therapy for the treatment of inflammatory conditions such as rheumatoid arthritis. The use of TNF blocker agents to treat rheumatoid arthritis has been increasing among the aging U.S. population and treatment for the disease is becoming more and more costly.(1)

Because of Prime's close working relationship with many large health plans, Prime is uniquely positioned to analyze both pharmaceutical and medical data to closely monitor drug safety, effectiveness, costs and prescribing practices. Through the evaluation of pharmacy claims of 4.4 million members from four major Blue Cross and Blue Shield Plans between July 2006 and June 2007, Prime was able to determine that members with an out-of-pocket cost greater than $250 were 4.6 times more likely to decline to fill their initial TNF-blocker medication.

In determining this, Prime found that more than six of seven members initiating TNF-blocker therapy had a per-claim, out-of-pocket expense of $100 or less with a low decline to fill rate of one in 50. The study also found that this decline to fill rate increased to at least one out of every 10 members when the out-of-pocket expense was $251 to $500 and grew to one out of every 5 when members paid the entire cost of greater than $1000. Members generally need to pay approximately $250 when they have a 20% coinsurance pharmacy benefit and they would have to pay the entire cost early in the year when their pharmacy benefit is a consumer directed healthcare product.

"From our findings, we believe that members who have an out of pocket expense of less than $100 per prescription fill are more likely to initiate treatment," said Patrick Gleason, PharmD, Director of Clinical Outcomes Assessment at Prime. "We also believe that the $250 out-of-pocket rate is an important value, and one that insurers should give consideration to, as it represents the expected out-of-pocket cost for members with a 20 percent co-insurance benefit."

Prime Therapeutics will be presenting this study at the 20th Annual American Managed Care Pharmacy (AMCP) Conference on April 18 in San Francisco. Other Prime poster presentations include:

-- Pioglitazone (Actos(R)) and Rosiglitazone (Avandia(R)) 2007

Utilization Trends and Prevalence of Cardiovascular Risk among

Rosiglitazone Utilizers

-- Pharmacy Management Heartburn: Lack of Medical Correlation with Proton

Pump Inhibitor Utilization

-- Assessment of Modafinil (Provigil(R)) Utilization Management

Opportunity: Integrated Medical and Pharmacy Claims Analysis

-- Statin Step-Therapy Program: Impact on Utilization and Cost

-- Assessment of an Insurer Letter to Providers Requesting They Initiate

Statin Therapy for Members at Major Adverse Cardiovascular Event Risk

1. Scott, D.L., Kingsley, G.H. Tumor necrosis factor inhibitors for

rheumatoid arthritis. NEJM 2006;355:704-12. Prime Therapeutics 2006

Drug Trend Insights

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 14.6 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... Viejo, CA (PRWEB) , ... April 30, 2017 ... ... animations created exclusively for use in Final Cut Pro X. Editors can pick ... and more. Easily change the highlights, mid levels and shadows using simple color ...
(Date:4/29/2017)... ... ... TransDark is a set of dynamic transitions that feature inverted, prismatic, and ... set a single keyframe in Final Cut Pro X. Pick and choose ... dynamic transitions that momentarily splits the RGB layers of pictures and videos before revealing ...
(Date:4/28/2017)... ... , ... An April 24th article on Yahoo! Beauty discusses the case of Jessica ... a weight loss surgery. The woman, declaring “I will not hate my body anymore!” posted ... dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers its patients ...
(Date:4/28/2017)... UT (PRWEB) , ... April 28, 2017 , ... Beginning ... some of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ... be changing the formula in the following ways:, , Removal ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... , April 24, 2017 Solentim, the ... announced the addition of a major new product ... Plate Seeding,). The VIPS has been developed for ... well microplates as part of the process to ... a simple and more reliable solution when compared ...
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
Breaking Medicine Technology: